ACTRN12605000706673已完成2 期
A PHASE II STUDY OF IRINOTECAN, LEUCOVORIN AND FLUOROURACIL IN ADVANCED GASTRIC CANCER TO IMPROVE DISEASE FREE SURVIVA
Site - Investigator Initiated . AGITG sponsored trial, conducted through NHMRC CTC0 个研究点目标入组 80 人开始时间: 2005年11月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Patients must have clinically documented locally advanced or metastatic adenocarcinoma of the stomach and histologic confirmation of the diagnosis. Patients must have measurable disease (lesions > 1x1 cm by clinical measurement or chest x-ray, and > 2x2 cm by CT or ultrasound). Patients must have a performance status of 0-2 on the ECOG Performance Scale. Patients must have a predicted life expectancy of at least 12 weeks. Patients must have a pre-treatment granulocyte count (ie., segmented neutrophils + bands) of > 1.5 x 109/L, a haemoglobin level of 90 gm/L and a platelet count of > 100 x 109/L. Patients must have adequate renal function as documented by a serum creatinine 200 mol/L. Patients must have adequate hepatic function as documented by a serum bilirubin 25 mol/L, regardless of whether patients have liver involvement secondary to tumour. Aspartate transaminase (AST, SGOT) must be 3x institutional upper limit of normal unless the liver is involved with tumour, in which case the aspartate transaminase must be 5x institutional upper limit of normal. Patients must be and geographically assessable and physically capable of completing study investigations as required. Patients must give written informed consent.
排除标准
- •Patients who have previously received CPT-11 or topotecan. Patients who have received chemotherapy in both the neoadjuvant / adjuvant setting and for recurrent/metastatic disease. (Prior chemotherapy is permitted under certain conditions see section 8.1). Patients with any active or uncontrolled infection, including known HIV infection. Patients with psychiatric disorders that would interfere with consent or follow up. Patients with a history of myocardial infarction within the previous six months or congestive heart failure requiring therapy. Patients with a history of prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for at least five years. Pregnant or lactating women. Men and women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. Presence of clinically apparent central nervous system metastases or carcinomatous meningitis. Patients with a history of seizures are ineligible. Patients receiving phenytoin, phenobarbital, or other antiepileptic prophylaxis are ineligible. Patients with uncontrolled diabetes mellitus, defined as random blood sugar > 15 mmol/L. Patients with baseline serum calcium 2.70 mmol/L. Patients with known Gilbert's Disease, as these patients may have excessive CPT-11-induced toxicity. Patients with any other severe concurrent disease which, in the judgement of the investigator, would make the patient inappropriate for entry into this study.
研究者
相似试验
未知
1 期
A Phase 1b Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) Drug Product in Japanese Subjects With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a FluoropyrimidineJPRN-jRCT2080221386Eli Lilly Japan K.K.
进行中（未招募）
1 期
A randomised phase II study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer after failure of Oxaliplatin-containing chemotherapy - FOLFIRI plus ZD4054 in colorectal cancers refractory to oxaliplatiMetastatic Colorectal CancerEUCTR2009-012151-23-GBCardiff University122
已完成
2 期
A phase II study of Irinotecan (CPT-11) for Leiomyosarcoma of Uteruseiomyosarcoma of UterusJPRN-C000000448Japanese Gynecologic Oncology Group35
已完成
1 期
A Phase I/II Study of Amrubicine and Irinotecan in Patients with Advanced Small Cell Lung Cancersmall cell lung cancerJPRN-C000000150West Japan Oncology Group40
进行中（未招募）
不适用
En fase II undersøgelse af Irinotecan og Panitumumab som 3. linje behandling til patienter med metastaserende colorectal cancer uden KRAS mutationer.EUCTR2008-004923-48-DKVejle Sygehus